By the Peptevity Research Desk — vendor-neutral, evidence-graded. Scientific review: independent reviewer pending — how our review works.

Are Peptides Legal? The US Legal Status of Peptides (2026)

Direct answer

"Are peptides legal?" has no single yes/no answer in the United States, because "peptide" spans three different legal lanes. FDA-approved peptide drugs — such as semaglutide, tirzepatide, tesamorelin (Egrifta), sermorelin, leuprolide, and octreotide — are legal as prescription medicines for their approved uses (FDA: Egrifta approval). Compounded peptides are legal only within the narrow framework of sections 503A/503B of the FD&C Act, which turns on the FDA's bulk-drug-substances lists (FDA: 503A bulks). Research-grade peptides sold "for research use only — not for human consumption" are not approved for human use at all. On 2026-04-15 the FDA announced it was removing 12 peptides from the interim 503A Category 2 list — a procedural change, not an approval — with a Pharmacy Compounding Advisory Committee hearing on July 23–24, 2026 and a second review by February 2027. This page is information, not legal advice.

A peptide is just a short chain of amino acids, and thousands exist — from insulin (a fully approved drug) to a research-only sequence with no human-safety record. So the legality question is really three questions in a trench coat. The rest of this page takes the honest approach: sort any given peptide into one of three lanes, then ask what the FDA primary sources say about that lane, on this date. Throughout, we keep the date attached, because the compounding lane in particular shifts quickly — track changes on the living 2026 regulatory tracker.

The three lanes are: FDA-approved drugs, compounded preparations (503A/503B), and research-use-only material. They carry very different legal weight, and most online confusion comes from collapsing them into one.

Several peptides are FDA-approved drugs, unambiguously legal to prescribe and dispense for their approved indications. They went through the full new-drug-application process — safety, efficacy, manufacturing — and are regulated like any other prescription medicine.

  • Tesamorelin (Egrifta) — a synthetic growth-hormone-releasing-factor analog, approved by the FDA on November 10, 2010 to reduce excess visceral abdominal fat in HIV-associated lipodystrophy (FDA summary review, NDA 022505).
  • Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — GLP-1 / dual GIP-GLP-1 incretin drugs, FDA-approved and legal as branded prescription products (FDA: GLP-1 compounding clarification).
  • Sermorelin, leuprolide, octreotide and other established peptide drugs — long-marketed approved products in their respective approved uses.

The distinction that matters: an FDA-approved peptide is legal as the approved finished drug product, dispensed against a prescription. That legality does not extend to a vial of the same molecule labeled "research use only," nor does it mean every formulation or route of that peptide is approved. For the difference between an investigational peptide and an approved one, see our note on investigational vs approved peptides.

Investigational peptides are a separate case. A peptide in clinical trials is not yet approved. For example, retatrutide — Eli Lilly's triple agonist (GIP/GLP-1/glucagon) — is in the Phase 3 TRIUMPH program and, as of June 2026, is not FDA-approved; no new-drug application had even been submitted to the FDA as of this review date, with Lilly's filing reported as on track for late 2026, which would put any approval decision well into 2027 or later (Lilly: what to know about retatrutide). It is nonetheless sold gray-market as a "research peptide," which is precisely the lane-confusion this page warns about: an unapproved investigational drug being marketed as if "research use only" made human use lawful. It does not.

Lane 2 — Compounded peptides and the 503A framework

This is the lane that generates the most 2026 headlines, and the one most often misreported. Compounding is the preparation of a customized medication by a licensed pharmacy. Under the FD&C Act, compounders operate under section 503A (state-licensed pharmacies and physicians) or section 503B (registered outsourcing facilities). A compounder generally may not use a bulk drug substance unless it is the subject of an FDA-approved drug, appears on the FDA's bulk-drug-substances ("bulks") list, or is on the relevant drug-shortage list (FDA: 503A bulks).

The interim Category 1 / 2 / 3 system

While the FDA evaluates substances nominated for the 503A bulks list, it has used an interim policy that sorts nominated bulk substances into three categories (FDA: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A — Federal Register, Jan 7, 2025):

  • Category 1 — nominated with sufficient supporting information, may be eligible for the bulks list, and not on any other disqualifying list. For Category 1 substances, the FDA says it does not intend to take action against compounders who meet the guidance conditions. This is the "enforcement-discretion" bucket.
  • Category 2 — nominated with sufficient information to evaluate, but the FDA identified significant safety risks pending further evaluation, so it does not extend the Category 1 enforcement-discretion policy. In plain terms: a "do-not-compound, for now" bucket.
  • Category 3 — nominated with insufficient supporting information for the FDA to evaluate; not eligible for the Category 1 policy.

Being on a list is not the same as being approved. Category 1 is enforcement discretion, not approval; Category 2 is a flagged-risk holding pattern; Category 3 is "we cannot even assess this yet." For the everyday meaning of the RUO label that overlaps this lane, see what "research use only" means.

What the April 15, 2026 removal did — and did not — do

On 2026-04-15, the FDA announced it would remove 12 peptides from interim Category 2 (effective approximately April 22, 2026) because the nominations supporting those listings were withdrawn by the nominators. The 12 were widely reported as BPC-157, TB-500, KPV, MOTS-c, emideltide (DSIP), epitalon, Semax, Cathelicidin LL-37, dihexa acetate, GHK-Cu, PEG-MGF, and Melanotan II (FDA PCAC meeting calendar, July 23–24, 2026).

Here is the part secondary coverage routinely garbles. Removal from Category 2 is not approval, and it is not authorization to compound. It does not place these peptides on the 503A bulks list, and it does not move them into the Category 1 enforcement-discretion bucket. With the nominations withdrawn, the FDA simply has no active nomination to keep evaluating, so the substances drop off the interim list and sit in a regulatory gray area until the agency takes final action through the advisory-committee process. The popular "14 peptides are legal again" framing is wrong on both the count and the conclusion. The disciplined reading is: the safety-flag list shrank for procedural reasons; the legal status of compounding these peptides remains unsettled.

The July 23–24, 2026 PCAC hearing (7 peptides)

The FDA scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23–24, 2026 at the FDA White Oak campus, under docket FDA-2025-N-6895, to consider whether to add a first group of peptides to the 503A bulks list (FDA PCAC meeting calendar):

  • July 23, 2026 — BPC-157, KPV, TB-500, and MOTS-c (each as free base / acetate).
  • July 24, 2026 — emideltide (DSIP), Semax, and epitalon (each as free base / acetate).

That is the seven-peptide group. A PCAC vote is a recommendation; the FDA makes the final listing decision afterward. Until that decision, none of these are on the 503A bulks list. We will log the outcome on the 2026 regulatory tracker.

The second review group (by February 2027)

The remaining peptides from the April removal are slated for a separate PCAC review expected before the end of February 2027. This second group includes GHK-Cu and Melanotan II (alongside Cathelicidin LL-37, dihexa acetate, and PEG-MGF). This matters because secondary sources frequently misplace GHK-Cu and Melanotan II into the July 2026 hearing — they are not in it. If your interest is the copper peptide specifically, see the dated status in our GHK-Cu monograph.

A related but separate story: compounded GLP-1s

The GLP-1 weight-loss drugs follow a different mechanism within this lane. Compounders were permitted to make semaglutide and tirzepatide while those drugs were on the FDA shortage list. The FDA determined the tirzepatide shortage resolved (late 2024) and the semaglutide shortage resolved (February 21, 2025), after which the enforcement-discretion windows for compounding closed — 503A semaglutide discretion ended around April 2025 — and the FDA later proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list (FDA: clarifies policies for compounders as GLP-1 supply stabilizes). The lesson: "legal to compound" is conditional and time-bound even for an FDA-approved molecule.

Lane 3 — Research-use-only ("not for human consumption")

A large share of peptides sold online — BPC-157, TB-500, and most of the names above — are marketed as "research use only — not for human consumption." That label is a legal category, not a marketing flourish. Material in this lane is not an FDA-approved drug, not a dietary supplement, and not a food, and there is no lawful basis to sell or administer it for human use. The US Department of Defense's Operation Supplement Safety program states plainly, for BPC-157, that it "is an unapproved drug and cannot be legally prescribed or sold over the counter," and is not a recognized dietary ingredient (DoD OPSS).

So "I bought it legally as a research chemical, therefore using it is legal" does not follow. Purchasing a labeled research reagent and self-administering it are different acts under different rules, and the RUO label exists precisely to mark that the material has not cleared the bar for human use. We explain that label in full on what "research use only" means, and Peptevity publishes no human dosing or self-administration instructions for any compound in this lane.

Even where a peptide is legally available in one lane, it can be banned in competition. The World Anti-Doping Agency (WADA) prohibits many peptides at all times. The catch-all S0 (non-approved substances) category covers any substance not approved by a government health authority for human therapeutic use — pre-clinical, clinical-development, designer, or veterinary — and peptide hormones and growth factors fall under S2 (WADA Prohibited List). BPC-157, for instance, is prohibited under the 2026 list. For athletes subject to anti-doping rules, "is it FDA-legal?" and "is it WADA-allowed?" are independent questions, and the second one can end a career regardless of the first.

What this means, in plain terms (as of 2026-06-09)

  • FDA-approved peptide drugs are legal by prescription for their approved uses; that is the cleanest lane.
  • Compounded peptides are legal only within the 503A/503B framework, which depends on the FDA's bulks and shortage lists — and that framework is in flux for the peptides at issue in 2026.
  • The April 15, 2026 removal of 12 peptides from Category 2 is not approval; those peptides sit in a gray area pending PCAC review (seven on July 23–24, 2026; a second group by February 2027).
  • Research-use-only material is not legal for human use, regardless of how easy it is to buy.
  • Sport adds a separate ban layer under WADA that is independent of FDA status.

If you take one thing from this page: do not let a vendor collapse these lanes for you. "Peptides are legal" is true for some peptides in some lanes and false for others, and the date matters. For the compound-by-compound picture, start with our evidence-graded monographs — for example the BPC-157 monograph and the GHK-Cu monograph — and watch the living 2026 regulatory tracker. And again: this is general information, not legal advice.

Frequently asked questions

Are peptides legal in the United States? Some are, some are not — it depends on the lane. FDA-approved peptide drugs (e.g., semaglutide, tirzepatide, tesamorelin) are legal as prescription medicines for their approved uses (FDA). Compounded peptides are legal only within the 503A/503B framework, which is unsettled for many peptides in 2026 (FDA). Research-use-only peptides are not legal for human use. This is information, not legal advice.

Did the FDA make 12 peptides legal in April 2026? No. On April 15, 2026 the FDA announced it was removing 12 peptides from the interim 503A Category 2 list (effective ~April 22, 2026) because the supporting nominations were withdrawn. Removal is not approval and is not authorization to compound — the peptides moved into a regulatory gray area pending advisory-committee review, not onto the bulks list (FDA PCAC calendar).

Which peptides is the FDA reviewing on July 23–24, 2026? Seven, under docket FDA-2025-N-6895: BPC-157, KPV, TB-500, and MOTS-c on July 23, and emideltide (DSIP), Semax, and epitalon on July 24 (FDA PCAC calendar). GHK-Cu and Melanotan II are not in this hearing; they are in a second review group expected by February 2027.

Is it legal to buy "research use only" peptides? A labeled research reagent may be sold for laboratory research, but it is not an FDA-approved drug, supplement, or food, and is not legal to sell or use for human consumption (DoD OPSS). Buying a research chemical does not make human use lawful. Peptevity publishes no dosing or self-administration guidance.

Is retatrutide legal / FDA-approved? As of June 2026, retatrutide is an investigational Eli Lilly drug (a GIP/GLP-1/glucagon triple agonist) in the Phase 3 TRIUMPH program and is not FDA-approved — no application had been submitted to the FDA as of this review date, with Lilly's filing reported as on track for late 2026 (Lilly). It is separately sold gray-market as a "research peptide," which does not make it approved or legal for human use.

Are peptides banned in sports? Many are. WADA prohibits non-approved substances at all times under S0, and peptide hormones / growth factors under S2 (WADA). A peptide can be banned in competition regardless of its FDA status.

How we sourced this page

Every regulatory claim above is anchored to an FDA, WADA, or DoD primary source, with the status date attached, per our sourcing and citation policy. Peptevity carries no advertising, no affiliate links, and sells nothing — see our conflict-of-interest and funding statement. Nothing here is legal advice.

Primary sources

External references appear as citations only; none of the cited institutions endorse, review, or are affiliated with Peptevity. This page is general information and is not legal advice.

Related on Peptevity

Every claim above is cited inline to a primary source. See how we grade evidence and our sourcing & citation policy.